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B-Type Natriuretic Peptide Levels in Preterm Neonates
With Bronchopulmonary Dysplasia: A Marker of Severity?
Vaneet Kumar Kalra, MD,1* Sanjeev Aggarwal, MD,2 Prem Arora, MD,1 and Girija Natarajan, MD1
Summary. Rationale for the Study: B type natriuretic peptide (BNP) is a hormone released in
response to stretching of the ventricular wall. The role of BNPas a biomarker of bronchopulmonary
dysplasia (BPD) has not been clarified. Objective: To determine if plasma BNP concentrations
correlate with the severity of BPD. Methods: This prospective observational case control study
included 60 preterm infants (32 weeks); 27 infants had no/mild BPD, 19 had moderate and 14
had severe BPD. BNP levels were measured at 362 weeks PMA or within a week of discharge
home. Groups were compared using Mann–Whitney’s U-test, Kruskal–Wallis, and bivariate
regression. Results: Median (IQR) plasma levels of BNP in infants with moderate/severe BPD
infants (n¼33) were higher as compared to those with no/mild BPD (n¼27); 27.1 (12.1–43.5) pg/
ml versus 9.3 (6–18.5) pg/ml;P<0.05 (MannWhitney U). Median (IQR) BNP levels in infants with
severe BPD (n¼14), 43.5 (28.4–189) pg/ml differed significantly from levels in those with
moderate (n¼19), 22.8 (10.3–27.7) pg/ml; mild (n¼16), 11.5 (6.6–44.5 pg/ml); or no (n¼11), 8.1
(5–12.6 pg/ml) BPD (P<0.001 Kruskal–Wallis). Based on receiver operating characteristic
curves, BNP>24.4 pg/ml at 362 weeks PMA or discharge home was 85.7% sensitive and
76.1% specific for severe BPD. Conclusions: An elevation in plasma BNP was significantly
associated with severe BPD. We speculate that plasma BNP measurement in infants with BPD
may aid in risk-stratification and further targeted therapies. Pediatr Pulmonol. 2014; 49:1106–
1111.  2013 Wiley Periodicals, Inc.
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WHAT IS KNOWN ON THIS SUBJECT
Bronchopulmonary dysplasia (BPD) is an important
cause of morbidity and mortality among premature
neonates. BPD may be associated with cardiovascular
sequelae. Conventional echocardiogram may not be
sensitive in detecting increased pulmonary vascular
pressures associated with BPD.
WHAT THIS STUDY ADDS
Infants with BPD have higher levels of B type
natriurteic peptide as compared to controls. An elevation
in plasma B type natriurteic peptide was significantly
associated with severe BPD.
BACKGROUND
BPD is a chronic lung disease that occurs predomi-
nantly in preterm infants and, historically, is considered
secondary to underdeveloped lungs and mechanical
ventilation.1 Despite improvements in clinical care, the
incidence of BPD has remained unchanged and a “new
BPD” has evolved.2 The new BPD is characterized by
interference in vascular and alveolar development and
dysregulation of pulmonary vascular development with
fewer pulmonary vessels and structural remodeling.3 In
addition, pulmonary vessels may have increased respon-
siveness to oxygen (O2), with mild hypoxia causing a
marked elevation of pulmonary artery pressure.4 There-
fore, infants with BPD are at risk of developing
pulmonary hypertension (PHT).5 Besides pulmonary
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vascular changes, BPD has been shown to cause diastolic
dysfunction and impaired left ventricle myocardial
performance index.6
The cardiac effects of BPD are not routinely evaluated.
When undertaken, echocardiography (ECHO) is used as a
primary screening modality. It is limited, however, by its
availability, expense and lack of sensitivity in diagnosing
PHT.7 Cardiac catheterization, considered as the gold
standard for diagnosis and assessment of severity of PHT,
is an invasive procedure and is only available in few
tertiary centers.
B-type natriuretic peptide (BNP) is a hormone secreted
by ventricular myocytes in response to stretch, that is,
volume or pressure overload. It is secreted as an inactive
precursor pro-BNP which is then cleaved into BNP and N
terminal pro BNP (NT- pro BNP). BNP plays an
important role in regulating systemic blood pressure
and natriuresis.8 It is routinely used in the diagnosis and
prognosis of congestive heart failure in adults.9 High BNP
and NT- pro BNP concentrations have been previously
shown in infants and children with heart disease and
neonates with patent ductus arteriosus (PDA), persistent
PHT, and as a guide for prophylactic therapy of PDAwith
indomethacin.10–13 While its use has drifted into clinical
practice, there are currently scant data on BNP concen-
trations in preterm infants with BPD.
The purpose of this study was to evaluate the utility of
BNP as a biomarker of BPD. We sought to compare
plasma BNP concentrations at 36 2 weeks post-
menstrual age (PMA) or discharge home, in premature
infants (32 weeks gestation at birth) with and without
BPD. Infants were further categorized as no, mild,
moderate, and severe, according to the NIH severity-
based classification and plasma BNP levels were
compared among these categories.14 According to the
classification, preterm infants (32 weeks gestation at
birth) requiring supplemental oxygen at 28 days of age are
diagnosed asmild BPD if they are on room air at 36 weeks
PMA or discharge home, as moderate BPD if they require
<30% supplemental oxygen and as severe BPD if they
require either 30% oxygen or positive pressure
ventilation, including continuous positive airway pressure
at 36 weeks PMA or discharge home.14 We hypothesized
that plasma BNP concentrations at 36 2 weeks PMA or
discharge home would be significantly elevated in
preterm neonates with BPD, compared to those without
BPD and with increasing severity of BPD.
METHODS
Patient Population
This was a prospective observational case-control study
conducted in the Neonatal Intensive Care Unit (NICU) and
special care nursery at Hutzel Women’s Hospital (HWH)
and the NICU at Children’s Hospital of Michigan (CHM).
All infants, either inborn or transferred from an outside
hospital, were considered eligible for enrolment, provided
their gestational age was 32 weeks by the best obstetric
estimate. Infants with congenital heart disease (except
patent foramen ovale), multiple congenital anomalies,
hemodynamic instability requiring pressors, active blood-
stream or respiratory infections, renal insufficiency or
sudden clinical deterioration were excluded from the
study. The study was approved by the Institutional Review
Board (IRB) at Wayne State University.
Medical records were reviewed to determine eligibility
and seek parental consent. Once determined to be eligible,
parents were approached for a written consent. Study
procedures included blood draw of 0.25ml for measure-
ment of BNP concentration at 36 2 weeks PMA or
discharge home.
Measurement of Plasma B-Type Natriuretic
Peptide
BNP was measured using the Food and Drug
Administration-approved Biosite Triage BNP kits (Bio-
site Diagnostics Inc., Alere, San Diego, CA). Its inter-
assay imprecision is 9.9–12.2%. The assay, which utilizes
a disposable device, was performed by a single
investigator (V.K.) after a brief training and took
approximately 15min. Whole blood (0.25ml) is added
to the sample port of the device. The filter in the device
separates the blood cells from the plasma. The separated
plasma migrates through the diagnostic lane with the help
of capillary action and reacts with fluorescence-tagged
murine polyclonal antibodies against the ring structure of
BNP. Excess plasma washes away the unbound antibody.
An internal calibration curve is used to quantify the
fluorescence intensity of the BNP assay zone.
The medical records were reviewed for data abstrac-
tion. Data collected included infant demographics, birth
weight and its category (appropriate, small or large-for
gestational age, mode of delivery and Apgar score at
5min.15 Maternal data (ethnicity, use of antenatal
steroids, duration of rupture of membranes, and cho-
rioamnionits) were also collected. Clinical data including
age when BNP was measured, days of O2 or ventilation
requirement, morbidities such as necrotizing enterocolitis
(NEC), intraventricular hemorrhage (IVH), severe IVH
(grade 3 or 4), PDA requiring treatment, effective O2
delivery, and medications for PHTwere reviewed.16,17 In
ventilated patients, peak respiratory severity scores (RSS)
were calculated using standard formula as the product of
mean airway pressure and fraction of inspired O2 on the
day of BNP sampling and 2 and 7 days earlier.18 BPD
severity was graded as no, mild, moderate and severe
according to the severity-based classification of National
Institute of Health (NIH).14
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Cardiac imaging was not done specifically for this
study. Reports of echocardiograms (ECHOs) performed
for clinical carewere reviewed to rule out congenital heart
disease (except PFO) and myocardial dysfunction.
Cardiac catheterization, done at any time, was reviewed
for presence of PHT.
Statistical Analysis
Reported mean SD plasma BNP concentrations at 1–
6 months of life are 21 10 pg/ml.19 We expected a 25%
difference in the BNP values between patients with BPD
and controls, based on a 50% higher BNP level in patients
with stable chronic obstructive pulmonary disease
without any evidence of PHT, compared to controls.20
For an alpha (for the two-tailed test) of 0.05 and beta of
0.2, a sample size of 27 in each group was calculated to
give the study a power of 80% and yield a statistically
significant result.
Data analysis was performedwith SPSS 19 (SPSS, Inc.,
Chicago, IL). Descriptive data included mean (SD),
median (interquartile range) and number (percent) as
appropriate. Chi square test was used to compare
descriptive variables between groups. The Kolmo-
gorov–Smirnov test of normality showed a non-normal
distribution of continuous variables and therefore, non-
parametric tests (Mann–Whitney U, Spearman correla-
tion, Kruskal–Wallis) were used for further comparisons.
BNP was evaluated as a marker of BPD using area under
receiver operating characteristic (ROC) curves. Regres-
sion analysis was used to examine the association
between BPD and gestational age, C-section and PDA
(variables found to be significantly different in bivariate
comparisons) and BNP. A P-value of <0.05 was taken as
statistically significant.
RESULTS
A total of 60 preterm infants were studied; 40 (66.7%)
infants were enrolled from the Level III inborn unit at
HWH and 20 (33.4%) were enrolled from the regional
referral Level IV NICU at CHM. Figure 1 is a description
of patient accrual. The 20 infants enrolled at CHM were
derived from 49 infants who met study eligibility criteria
and were at CHM NICU at 36 2 weeks PMA or
discharge home. These infants were transferred from
other Level III NICUs for the management of complex
medical or surgical concerns such as airway evaluation for
failure to extubate and placement of ventriculoperitoneal
shunt.
The cohort was predominantly male (58.3%), appro-
priate for gestational age (81.7%), African-American
(68.3%), and delivered via C section (65%). The median
(IQR) gestational age and birth weight were 26 (24–28)
weeks and 885 (700–1,125) g, respectively. Antenatal
steroids were administered in 53 (88.3%) infants, with a
complete course in 40 (67%) cases. Ten (16.7%) mothers
had signs of clinical chorioamnionitis and 25 (41.7%) had
histologic chorioamnionitis. Apgar scores 5 at 5min of
life were noted in 12 (20%) infants. Median (IQR)
surfactant doses and weight at the time of BNP
measurement were 1 (1–2.75) and 1,922 (1,770–
2,221) g, respectively. Of our samples, 24/60 were prior
to 36 weeks PMA at the time of discharge and 15/60 were
drawn subsequent to 36weeks. Themedian (IQR) PMAat
sampling was 36 (35–37) weeks. An ECHO was
performed at some point during hospitalization in 45
(75%) infants; only 14 (23%) underwent an ECHOwithin
14 days of BNP measurement. Of the 33 infants with
BPD, 12 (36%) had an ECHO within 14 days, and 32
(97%) had an ECHO at some point during their NICU
stay. A PDA was documented to be absent on the latest
ECHO or was surgically ligated in 30 (91%) of the infants
with BPD. The latest echocardiogram showed a tiny PDA
in two infants. Two infants, who had findings suggestive
of elevated pulmonary pressures on cardiac catheteriza-
tion had BNP levels of 324 and 400 pg/ml.
Of the study cohort, 33 (55%) infants required
supplemental O2 at 36 weeks PMA or discharge home
and were characterized as having BPD, whereas 27 (45%)
infants were in the no BPD group. Table 1 is a description
of the respiratory support—O2 delivered and RSS in
infants with and without BPD at the time of BNP
measurement and 2 and 7 days prior to BNP measure-
ment. The lack of significant differences over time
suggest stable respiratory support at the time of BNP
measurement. Two infants without BPDwere on O2 at the
time of BNP sampling (PMA 33 4/7 weeks and 36 0/7
weeks); both were discharged home without O2 within a
week of sampling and before completion of 36 weeks
PMA. At BNP measurement, 13 (21.7%) infants were
receiving antimicrobial therapy but none had positive
cultures from any site for more than a week. All infants
Fig. 1. Flow diagram of eligible patients.
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had good urine output with a median (IQR) serum
creatinine of 0.3 (0.2–0.4)mg/dl. Table 2 is a comparison
of the clinical characteristics between the groups with and
without BPD, defined as O2 supplementation at 36 weeks
PMA. Median BNP concentrations were significantly
elevated in the BPD group (27.1 IQR: 12.1–43.5 vs. 9.3
IQR: 6–18.5 pg/ml, P¼ 0.003 by Mann–Whitney U),
compared to the no BPD group. Infants with BPD were
significantly more immature, more often African-Ameri-
can, had lower birth weights and had longer O2 and
ventilation need and higher rates of PDA requiring
treatment, compared to those without BPD. Five (8.3%)
infants with BPD required a tracheostomy and home
ventilation and two (3.3%) infants died. Binary regression
analysis was used to examine the association between
BNP concentration and BPD, with gestational age, C
section, and PDA (the variables found to be significantly
different in bivariate comparisons) as covariates. Gesta-
tional age, although not BNP, tended to be associated with
BPD (OR 0.71; 95% CI 0.49–1.01; P¼ 0.056).
Based on the NIH classification of severity of BPD, 14/
60 infants had severe, 19 hadmoderate, and 16 infants had
mild BPD. Eleven patients were not on any supplemental
oxygen at 28 days of life and were characterized as no
BPD. Median (IQR) BNP concentrations in the group
with severe BPD (43.5 IQR: 28.4–189 pg/ml) was
significantly elevated, compared to levels in groups
with moderate BPD (22.8 IQR: 10.3–27.7 pg/ml), mild
BPD (11.15 IQR: 6.6–44.5 pg/ml), or no BPD (8.1
IQR:5–12.6 pg/ml) (P< 0.001 Kruskal–Wallis). There
were no significant differences in BNP values between
those with moderate, mild, and no BPD. Figure 1 is a box
plot showing the median (IQR) BNP values in these four
categories.
We then performed regression analysis to examine the
association between severe BPD and gestational age, C
section, PDA, and BNP concentrations. BNP concentra-
tion (OR 1.05; 95% C.I 1.005–1.098; P¼ 0.028) was
independently associated with severe BPD, while
gestational age (P¼ 0.073) and PDA (P¼ 0.853) were
not. Plasma BNP at 36 2 weeks PMA at a cut-off value
of 24.4 pg/ml had an area under the ROC curve of 0.8
(95% CI 0.64–0.97), sensitivity of 85.7% and specificity
of 76.1% (Fig. 2).
TABLE 2—Clinical Characteristics of the Groups With and Without BPD
Variable n (%) or median (IQR) No BPD (n¼ 27) BPD (n¼ 33) P-value
Males 13 (48%) 22 (66.67%) 0.19
Gestational age (weeks) 28.1 (26.9–30.6) 25.3 (24–26.7) <0.001
Birth weight (g) 1,110 (940–1,250) 720 (615–875) <0.001
Small for Gestational Age 2 (7.4%) 5 (15.2%) 0.65
African-Americans 14 (51.9%) 27 (81.8%) 0.09
Any antenatal steroids 22 (81.5%) 31 (93.9%) 0.23
Maternal Histologic Chorioamnionits 11 (40.8%) 14 (42.4%) 0.71
PPROM >18 hr 7 (25.9%) 9 (27.3%) 1.00
Apgar score at 5 minutes 5 3 (11.1%) 9 (27.3%) 0.20
Inborn 18 (66.7%) 22 (66.7%) 1.00
C-section 22 (81.5%) 17 (51.5%) 0.03
Age at BNP (day of life) 53 (29–61) 82 (64.5–97.5) <0.001
Oxygen days 30 (8–60) 94 (72–115) <0.001
Ventilation days 2 (1–10) 60.5 (15.3–78) <0.001
Age extubated (days) 2 (0–8) 30 (12–75.5) 0.001
Any IVH 11 (40.8%) 14 (42.4%) 1.00
Severe IVH (Grade 3 or 4) 4 (14.8%) 8 (24.2%) 0.09
NEC 6 (22.2%) 12 (36.4%) 0.27
PDA 6 (22.2%) 19 (57.6%) 0.008
BNP level (pg/ml) 27.1 (12.1–75.5) 9.3 (6–18.5) 0.003
TABLE 1—Respiratory Support in InfantsWith andWithout BPD at the Time of BNPMeasurement, 2 and 7 Days Prior to BNP
Measurement
Median (IQR) BNP measurement day 2 days prior 7 days prior
O2 delivery (lpm)
BPD 0.26 (0.24–0.34), n¼ 21 0.26 (0.24–0.29), n¼ 20 0.26 (0.25–0.30), n¼ 19
No BPD 0.25, n¼ 2 0.23 (0.215–0.27), n¼ 2 0.24 (0.22–0.27), n¼ 3
RSS
BPD 2.46 (2.5–5.5), n¼ 12 3.2 (2.49–5.14), n¼ 13 3.2 (2.32–4.49), n¼ 12
No BPD N¼ 0 N¼ 0 3.0, N¼ 1
O2, oxygen; BPD, bronchopulmonary dysplasia; BNP, B-type natriuretic peptide; RSS, respiratory severity score.
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DISCUSSION
In this study, we found that BNP at 36 2 weeks PMA
or discharge home was significantly higher in preterm
infants with BPD, compared to those without BPD and in
those with severe BPD, compared to others. BNP retained
a significant independent association with severe BPD,
after adjustment for gestational age and clinical
differences.
Our results correlatewith the findings of Joseph et al.,21
who, in an observational pilot study of 11 infants, reported
higher NT-pro-BNP levels in preterm infants with BPD
and a correlation between levels and clinical severity of
respiratory disease. Cuna et al.22 in their retrospective
study of 25 preterm infants also reported higher BNP
levels in BPD infants with ECHO evidence of PHT. Our
findings, however, are contradictory to the findings of
Akcan et al. who, in a study of 28 subjects, did not find any
significant difference in NT-proBNP levels among
patients with a history of BPD compared to controls
and among infants with varying severity of BPD.23 This
difference in results is probably related to the time of
measurement, which in Akcan’s study was at a mean
postnatal age of 9.8 months when most of the clinical
findings of BPD become less severe.
In contrast to previous studies, our study measured
plasma BNP at a consistent time of 36 2 weeks PMA.
This later time was selected to examine the utility of BNP
as a marker of cardiac effects of BPD, which would have
developed over time and second, to allow the effects of
respiratory distress syndrome severity to wane. It also
obviated the initial postnatal changes in BNP concen-
trations.19 The interaction between gestational age, BNP
concentrations and BPD is complex. As expected,
gestational age of the group with BPD differed
significantly from the controls. To account for this, a
consistent PMA was selected for sampling. Moreover
previous studies have reported comparable BNP levels in
preterm and term infants after 28 days of life.19,24
The mechanism of elevation in BNP in BPD is not
entirely clear. BNP has been previously shown to be a
counter-regulatory hormone released in response to
sustained pulmonary hypoxia.25 It induces pulmonary
relaxation and plays a role in modulating the pulmonary
hypertensive response to chronic hypoxia.26 In addition,
BNP is considered a biomarker of disease severity and
prognosis in adult patients with PHT.27 Elevated BNP
levels are seen in adult patients with stable chronic
obstructive pulmonary disease without evidence of
PHT.20 In contrast, among infants with acute respiratory
distress, plasma NT-pro BNP levels were significantly
increased in those with heart failure, compared to those
with lung disease.28 Elevation in BNP has been
demonstrated in adults with diastolic dysfunction.29
Therefore, elevated BNP in BPD could be related to
increased pulmonary vascular pressures, chronic pulmo-
nary disease itself, diastolic dysfunction or impaired
global left ventricular function.6,12
We recognize the limitations of our study which
include small sample size, range of gestational ages, lack
of ECHO at a defined time point in all infants and some
baseline differences between groups. Nonetheless, we
undertook a systematic evaluation of the utility of BNP in
BPD, defined by the standardized NIH-severity based
classification and found novel associations with severe
BPD. We meticulously excluded factors known to affect
plasma BNP such as active infections, renal insufficiency
and worsening respiratory condition.
PHT is an increasingly recognized accompaniment of
BPD and is associated with increased mortality and
morbidity.30 Collaco et al.30 have underscored the
“extreme phenotypic variability that exists among
preterm infants of similar gestational ages, making it
Fig. 2. BNP levels in four different groups of BPD severity.
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difficult to predict which infants are at increased risk for
developing PHT.” Many experts recognize that sensitive
and specific, rapidly measured bedside biomarkers are
needed to improve the diagnosis and management of
cardiac sequelae of BPD in preterm children. Such
biomarkers may potentially aid in the prognostication,
risk-stratification and targeted therapy in those at highest
risk. We believe the current study is a first step in this
direction. Further studies of serial BNP measurement for
prediction or early detection of severe BPD arewarranted.
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